This is cheap!!
I have no doubt and may close very strong.
its been working since $6.
Huge sector for years.
Do you think LP would actually help us here I believe in her but she drags her feet and if I have tuition payments I might have to sell some and miss the big move.
First Trust is sponsor.
June 15, 2015, 12:30 – 3:00 p.m. CDT Poster Session
Quantitative Monitoring of EGFR Mutations in Urinary Circulating Tumor DNA Enables Non-Invasive Pharmacodynamic Assessment of Anti-EGFR Drug Response
Single Cell and Circulating Free Nucleic Acid Sequencing Session, Abstract: # 29
Collaborator: Hatim Husain, M.D., UCSD Moores Cancer Center
•Urine-based EGFR ctDNA assay has been shown to outperform tissue biopsy for the detection of EGFR T790M mutations in metastatic lung cancer patients
•Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy, and months before detection of cancer progression with imaging
•Tracking ctDNA in urine enables determination of response to next generation EGFR T790M inhibitors within days of initial treatment
Add on news from MWBO and we explode !!
Bloomberg, CNBC, Fox Business making the headlines.
anatabine citrate is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory effects of anatabine.
Quotient Clinical, the Company's UK-based outsourced partner will immediately begin recruitment of healthy volunteers, with dosing to commence in February 2015, and with initial formulation PK data to emerge shortly after. Although study data management and analysis are expected to continue into August 2015, the Company anticipates having a substantial amount of data by MID-YEAR,